One could speculate that a key treatment strategy for progressive MS could involve targeting CNS-resident B cells, not aiming to suppress their traditional immunological (mis)behavior, but instead to quell a yet-to-be-discovered unconventional action, possibly related to secretion of an MS-specific myelin toxin into the CSF
First-line therapies, including metformin, sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and Glucagon-like peptide-1 (GLP-1) receptor agonists, are selected according to patient-specific risk factors
Tocopherols composition of portuguese wild mushrooms with antioxidant capacity
Simply put, BPC-157 helps tissue get more blood exactly where needed
It comes in a convenient 1fl oz each bottle and equipped with a precise dropper applicator
Provides continuous GH/IGF-1 elevation rather than pulsatile release